Edition:
United States

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

60.87USD
18 Aug 2017
Change (% chg)

$0.05 (+0.08%)
Prev Close
$60.82
Open
$60.72
Day's High
$61.24
Day's Low
$60.65
Volume
629,582
Avg. Vol
788,349
52-wk High
$63.09
52-wk Low
$43.14

Latest Key Developments (Source: Significant Developments)

Baxter reports second-quarter 2017 results
Wednesday, 26 Jul 2017 07:15am EDT 

July 26 (Reuters) - Baxter International Inc :Baxter reports second-quarter 2017 results and provides updated financial outlook for 2017 and 2020.Sees FY 2020 adjusted earnings per share $3.25 to $3.40.Q2 GAAP earnings per share $0.48 from continuing operations.Q2 revenue $2.6 billion versus I/B/E/S view $2.59 billion.Q2 earnings per share view $0.57 -- Thomson Reuters I/B/E/S.Sees FY 2017 earnings per share $2.34 to $2.40 from continuing operations excluding items.Sees Q3 earnings per share $0.58 to $0.60 from continuing operations excluding items.Sees FY 2017 GAAP earnings per share $1.85 to $1.95.Baxter International Inc says financial outlook for 2020 increased to reflect strong operational execution and ongoing business transformation initiatives.Q3 earnings per share view $0.56 -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $2.27 -- Thomson Reuters I/B/E/S.Baxter International Inc says Q2 sales within U.S. were $1.1 billion, advancing 4 percent.Baxter International Inc - for FY2017 raising financial outlook for year and now expects sales growth of approximately 3 percent on a reported basis.Company expects sales growth of approximately 4 percent on a reported basis for Q3.Baxter - Q2 international sales totaled about $1.5 billion, representing a 2 percent decrease on reported basis and 1 percent increase on a constant currency basis.Baxter International Inc - expects sales to grow approximately 4 percent on a compounded annual basis from 2016 to 2020.  Full Article

Baxter, Ramot at Tel Aviv university and Tel Aviv Sourasky Medical Center partner to bring new surgical innovations worldwide
Thursday, 6 Jul 2017 08:00am EDT 

July 6 (Reuters) - Baxter International Inc ::Baxter, Ramot at Tel Aviv University and Tel Aviv Sourasky medical center partner to bring new surgical innovations worldwide.Baxter International Inc says additional details of agreements were not disclosed.Baxter -under terms, will exclusively license TAU technology innovation momentum fund technology in one license agreement.Baxter -under terms, will exclusively TAU and TASMC technology in second license agreement.  Full Article

Baxter announces agreement with Dorizoe Lifesciences to further expand generic injectables pipeline
Wednesday, 14 Jun 2017 08:30am EDT 

June 14 (Reuters) - Baxter International Inc :Baxter announces agreement with dorizoe lifesciences to further expand generic injectables pipeline.Baxter International inc says financial terms of agreement were not disclosed.Baxter -dorizoe will work with baxter to perform certain product development activities, and baxter will hold worldwide manufacturing and commercialization rights.  Full Article

Baxter announces U.S. FDA approval, commercial launch of ready-to-use clindamycin injection in saline
Wednesday, 7 Jun 2017 11:00am EDT 

June 7 (Reuters) - Baxter International Inc :Baxter announces U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline.Baxter announces U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline.Baxter International - FDA approval and commercial launch of ready-to-use clindamycin injection in saline in three commonly prescribed formulations.Baxter International Inc- remains committed to providing additional premixes in an effort to advance pharmacy efficiency and patient care..Baxter International Inc - Baxter's ready-to-use clindamycin injection in saline is now available to customers in United States.  Full Article

Baxter and Mayo Clinic launch R&D collaboration to transform patient care
Wednesday, 31 May 2017 09:15am EDT 

May 31 (Reuters) - Baxter International Inc :Baxter and Mayo Clinic launch research and development collaboration to transform patient care.Baxter International Inc - ‍additional details of agreement were not disclosed​.Baxter International Inc - initial agreement is for a five-year period, with a five-year renewal option.  Full Article

Baxter International says in April became aware of criminal investigation by antitrust division of DOJ- SEC filing
Thursday, 4 May 2017 07:01pm EDT 

May 4 (Reuters) - Baxter International Inc ::in April 2017, co became aware of criminal investigation by U.S. DOJ, antitrust division and federal jury in U.S. District court for eastern district of Pennsylvania-filing.co and employee received subpoenas regarding manufacturing, selling, pricing and shortages of intravenous solutions and containers.  Full Article

Baxter International says received guidance from FDA clarifying regulatory pathway for new peritoneal dialysis technology
Wednesday, 3 May 2017 08:30am EDT 

May 3 (Reuters) - Baxter International Inc :Baxter International Inc - received guidance from FDA clarifying regulatory pathway for new peritoneal dialysis technology.Baxter International Inc - Baxter plans to have first patient on therapy with new system, as part of a clinical trial in 2018.Baxter International Inc - regulatory submission is expected in 2019 for new peritoneal dialysis technology.  Full Article

Baxter raises quarterly dividend
Tuesday, 2 May 2017 08:30am EDT 

May 2 (Reuters) - Baxter International Inc : :Increases quarterly dividend by 23 percent.Baxter raises quarterly dividend.Baxter International Inc - sets qtrly dividend of 13 cents per share.  Full Article

Baxter International Q1 revenue $2.5 billion
Wednesday, 26 Apr 2017 07:15am EDT 

April 26 (Reuters) - Baxter International Inc :Baxter reports first-quarter 2017 results and increases financial outlook for full-year 2017.Q1 GAAP earnings per share $0.50 from continuing operations.Q1 revenue $2.5 billion versus I/B/E/S view $2.43 billion.Q1 earnings per share view $0.51 -- Thomson Reuters I/B/E/S.Sees FY 2017 earnings per share $2.20 to $2.28 from continuing operations excluding items.Sees FY 2017 GAAP earnings per share $1.66 to $1.80.In Q2, expects flat sales growth on a reported basis, or approximately 2 percent on a constant currency basis.FY2017 earnings per share view $2.17 -- Thomson Reuters I/B/E/S.Baxter International - now expects sales growth of approximately 1 to 2 percent on a reported basis or 2 to 3 percent on a constant currency basis in 2017.Baxter International - expects sales growth of about 1 to 2 percent on a reported basis or 2 to 3 percent on a constant currency basis for FY 2017.Baxter International says expects earnings from continuing operations, before special items, of $0.55 to $0.57 per diluted share in Q2.Qtrly adjusted earnings of $0.58 per share.Q2 earnings per share view $0.52, revenue view $2.56 billion -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $2.17, revenue view $10.20 billion -- Thomson Reuters I/B/E/S.  Full Article

Third Point sells 5.9 mln shares of Baxter International's common stock in block trade on Feb 28
Wednesday, 1 Mar 2017 11:44am EST 

: Third Point LLC says on Feb 28, it sold about 5.9 mln shares of Baxter International Inc's common stock in a block trade at $50.35 per share . Third Point LLC now owns about 46 million shares of Baxter International's common stock as of feb 28 - sec filing . Third Point LLC previously owned 51.9 million shares of Baxter International's common stock as of Dec 31, 2016 according to its 13-F filing disclosed in Feb .Third Point​ now owns 8.5 pct stake in Baxter International following the block trade.  Full Article

Photo

Big-name U.S. hedge funds shed healthcare stocks during the rally in second-quarter

NEW YORK Several big-name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U.S. stock market higher, rallying amid a Republican effort to repeal and replace President Obama's signature healthcare law.